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RHBDF2-Regulated Growth Factor
Signaling in a Rare Human Disease,
Tylosis With Esophageal Cancer:
What Can We Learn From Murine
Models?
Vishnu Hosur* , Michelle L. Farley, Benjamin E. Low, Lisa M. Burzenski,
Leonard D. Shultz and Michael V. Wiles
The Jackson Laboratory, Bar Harbor, ME, United States
Tylosis with esophageal cancer syndrome (TOC) is a rare autosomal dominant
proliferative skin disease caused by missense mutations in the rhomboid 5 homolog 2
(RHBDF2) gene. TOC is characterized by thickening of the skin in the palms and feet and
is strongly linked with the development of esophageal squamous cell carcinoma. Murine
models of human diseases have been valuable tools for investigating the underlying
genetic and molecular mechanisms of a broad range of diseases. Although current
mouse models do not fully recapitulate all aspects of human TOC, and the molecular
mechanisms underlying TOC are still emerging, the available mouse models exhibit
several key aspects of the disease, including a proliferative skin phenotype, a rapid
wound healing phenotype, susceptibility to epithelial cancer, and aberrant epidermal
growth factor receptor (EGFR) signaling. Furthermore, we and other investigators have
used these models to generate new insights into the causes and progression of TOC,
including findings suggesting a tissue-specific role of the RHBDF2-EGFR pathway,
rather than a role of the immune system, in mediating TOC; and indicating that
amphiregulin, an EGFR ligand, is a functional driver of the disease. This review highlights
the mouse models of TOC available to researchers for use in investigating the disease
mechanisms and possible therapies, and the significance of genetic modifiers of the
disease identified in these models in delineating the underlying molecular mechanisms.
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INTRODUCTION
Gain-of-function (GOF) mutations in the human rhomboid 5 homolog 2 (RHBDF2) gene
constitutively activate epidermal growth factor receptor (EGFR) signaling to cause tylosis with
esophageal cancer syndrome (TOC; OMIM: 148500) (Blaydon et al., 2012; Saarinen et al., 2012;
Mokoena et al., 2018). RHBDF2 encodes the highly conserved, seven-transmembrane, rhomboid
protein family member RHBDF2 (Freeman, 2014). Although the mechanisms underlying
RHBDF2-mediated EGFR signaling are still emerging, gaining insights into these mechanisms will
contribute substantially to the discovery of unique drug targets for treating TOC and potentially
other related skin diseases.
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Substantial literature suggests that RHBDF2 regulates the
EGFR signaling pathway and its downstream signaling events,
including rapid wound healing and epithelial tumorigenesis,
through enhanced secretion of the EGFR ligand amphiregulin
(AREG) (Brooke et al., 2014; Hosur et al., 2014, 2017a). AREG is
synthesized as a pro-protein that requires conversion to an active
protein by a disintegrin and metalloprotease 17 (ADAM17), in
a process known as ectodomain shedding (Blobel, 2005). Two
models offer possible explanations of the role of RHBDF2 in
regulating AREG secretion. The first proposes that RHBDF2
directly interacts with ADAM17 and regulates its maturation,
trafficking, and ectodomain shedding activity. According to
the second model, RHBDF2 regulates AREG secretion through
ADAM17, as in the first model, but importantly, it does so
without altering ADAM17 sheddase activity. Further studies are
needed to establish specific biological functions and properties of
RHBDF2 in mediating AREG secretion in health and disease.
Currently there is no cure for TOC. To find a cure, two hurdles
must be addressed immediately. First, mouse models of human
TOC are critically needed to identify the relevant cell types, and
to understand the pathogenesis and how to approach therapeutic
treatment. Second, it is imperative to better understand the
mechanisms underlying RHBDF2-mediated EGFR signaling by
corroborating the significance of in vitro mechanistic findings in
mouse models of human TOC.
MURINE MODELS
Mouse models of human disease have long served a valuable
role in biomedical research. In recent years, we have generated
and validated mice carrying the human TOC disease mutation
p.P189L (Hosur et al., 2017a; Figure 1A, top panel, Figure 1B),
characterized a spontaneous mutation that results in a TOC
phenotype (Hosur et al., 2014), and used these mouse models
of TOC in studies in which we identified AREG as a functional
driver of the disease (Hosur et al., 2014, 2017a); established an
essential role for ADAM17 in mediating the disease (Hosur et al.,
2018); and, most recently, demonstrated that RHBDF2-AREG-
EGFR signaling, and not the immune system or surrounding
microenvironment, plays a role in mediating the disease (Hosur
et al., 2017b). These and other murine models of TOC (Table 1)
will be useful for methodically studying the molecular pathways
underlying TOC in further detail, for investigating the molecular
pathways underlying related proliferative skin diseases, and for
testing novel and existing therapeutics.
A Spontaneous Mouse Mutation: Curly
Bare (Rhbdf2cub/cub)
Spontaneous mouse mutations have been a valuable source of
animal models for studying heritable human diseases, both for
discovering the role of gene function and for understanding the
biological pathways involved. Johnson et al. (2003) described
a spontaneous recessive mouse mutation, named curly bare
(cub) that maps to the distal region of Chr 11 and exhibits a
hairless phenotype (Figure 1B). Hosur et al. (2014) reported
that the cub mouse mutation is an unusually large (12,681 bp)
deletion in the Rhbdf2 gene, resulting in the loss of exons
2–6. We also showed that even though the normal translation
initiation site (ATG) in exon 3 is missing, there is translation
from a downstream initiation site in exon 8, leading to a
∼63.5-kDa truncated protein rather than a full-length∼100-kDa
protein (Figure 1A; bottom panel). Histological analyses of skin
sections from Rhbdf2cub/cub mice revealed epidermal hyperplasia,
enlarged sebaceous glands, alopecia, and rapid cutaneous wound
healing (data not shown). Additionally, embryonic fibroblasts
isolated from Rhbdf2cub/cub mice exhibited a hyperactive EGFR
signaling phenotype mediated by enhanced secretion of AREG
(data not shown). Surprisingly, Rhbdf2 knockout (Rhbdf2−/−)
mice appeared normal (Figure 1B), with no skin or rapid
cutaneous wound-healing phenotype (Hosur et al., 2014; Siggs
et al., 2014), suggesting that Rhbdf2cub/cub is a GOF mutation
rather than a null mutation.
Next, to test the influence of mouse strain background on
the Rhbdf2cub/cub phenotype, we backcrossed the Rhbdf2cub/cub
mutation from the C57BL/6J background onto the MRL/MpJ
background for more than 20 generations, creating a true
congenic strain, MRL/MpJ-Rhbdf2cub/cub mice (Hosur et al.,
2017b). We observed not only the rapid cutaneous wound-
healing phenotype but also the hyperproliferative-skin phenotype
in these mice, suggesting that the Rhbdf2cub/cub mutation results
in a similar phenotype regardless of the mouse inbred strain
background.
Tylosis is strongly associated with esophageal squamous
cell carcinoma (Howel-Evans et al., 1958; Harper et al., 1970;
Ellis et al., 1994; Hennies et al., 1995); however, there is no
spontaneous incidence of esophageal cancer in Rhbdf2cub/cub
mice. Because cigarette smoking and alcohol consumption are
known risk factors for esophageal squamous cell carcinoma
(Montgomery et al., 2014), we reasoned that the Rhbdf2cub
mutation could increase the susceptibility to epithelial cancers
and tested the role of RHBDF2 in adenoma formation in
ApcMin/+mice, a mouse model of human colon cancer. We found
that a single allele of Rhbdf2cub can accelerate polyp formation
and reduce the survival rates of ApcMin/+ mice (data not shown)
(Hosur et al., 2014). Histological analysis revealed significantly
increased tumor size and an increased number of polyps in
ApcMin/+ Rhbdf2+/cub mice compared with ApcMin/+ Rhbdf2+/+
mice. Moreover, stimulated secretion of AREG was significantly
increased in intestinal epithelial cells isolated from ApcMin/+
Rhbdf2+/cub mice compared with ApcMin/+ Rhbdf2+/+ mice.
Together, these data suggest that GOF mutations in RHBDF2
accelerate tumor growth with an associated increase in AREG
secretion, suggesting a critical role for RHBDF2 in controlling
tumor growth through enhanced secretion of AREG.
A Genetically Engineered Mouse Model:
Rhbdf2P159L/P159L
The capacity of CRISPR/Cas9 technology to be used to
recapitulate patient variants in mouse models for various
human diseases is well established (Birling et al., 2017). Using
CRISPR/Cas9-mediated targeting and homology-directed repair
in C57BL/6J zygotes, we recently generated mice carrying
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FIGURE 1 | RHBDF2-regulated epidermal growth factor receptor signaling in TOC. (A) A schematic of the human RHBDF2 protein showing all four missense
mutations in the cytosolic N-terminus domain that underlie human TOC (top); a schematic of the mouse RHBDF2 protein showing the analogous human TOC
missense mutations (middle); a schematic of the truncated mouse RHBDF2 protein, encoded by the Rhbdf2cub gene, showing deletion of the cytosolic N-terminus
domain (bottom). Notably, in the truncated protein, the cytosolic N-terminus domain still retains amino acids 269–375. (B) Diagram showing that both spontaneous
(Rhbdf2cub/cub) and genetically engineered (Rhbdf2P159L/P159L) mouse models of human TOC exhibit a loss-of-hair phenotype. First, to validate that Rhbdf2cub/cub
and Rhbdf2P159L/P159L are gain-of-function (GOF) mutations rather than null mutations, we generated Rhbdf2 knockout (Rhbdf2−/−) mice and observed that
Rhbdf2−/− mice present with a normal hair coat, similarly to the wild-type (Rhbdf2+/+) mice, but very different from Rhbdf2cub/cub or Rhbdf2P159L/P159L mice.
Second, to validate that Rhbdf2cub and Rhbdf2P159L are mutant alleles of the Rhbdf2 gene, we generated Rhbdf2cub/− and Rhbdf2P159L/− mice, which exhibit a
sparse hair coat phenotype, suggesting that Rhbdf2cub and Rhbdf2P159L are mutant alleles of the Rhbdf2 gene. Third, we identified AREG and ADAM17 as genetic
modifiers of the TOC phenotype; genetic deletion of Areg or Adam17 in both Rhbdf2cub/cub and Rhbdf2P159L/P159L mice restores the normal skin phenotype in these
mice, suggesting that AREG and ADAM17 are essential mediators of the TOC phenotype. Lastly, we generated a B6-Tg(Hu-RHBDF2) mouse strain using a bacterial
artificial chromosome (BAC) containing the human RHBDF2 gene, which, similarly to Rhbdf2+/+ and Rhbdf2−/− mice, exhibits a normal hair coat. Together, our
results suggest that neither loss of RHBDF2 nor overexpression of RHBDF2, but GOF mutations, such as Rhbdf2cub and Rhbdf2P159L, induce an overt “EGFR
hyperactive” phenotype to cause TOC. (C) RHBDF2 GOF mutations enhance AREG secretion through ADAM17 in a tissue-specific manner, leading to EGFR
hyperactivation and in turn TOC.
the human TOC mutation p.P189L (p.P159L in mice) in
RHBDF2 (Figure 1A, top and middle panels, Figure 1B) and
showed that the Rhbdf2P159L GOF mutation enhances AREG
secretion to cause alopecia, rapid cutaneous wound healing,
hyperplasia, and hyperkeratosis (Hosur et al., 2017a). Also,
immunohistochemical analyses of skin sections from Rhbdf2+/+
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TABLE 1 | Mouse models of the human skin disease tylosis with esophageal cancer syndrome.
Strain Background Description Reference
Rhbdf2cub/cub C57BL/6J • Augmented secretion of amphiregulin (AREG). Johnson et al., 2003; Hosur
et al., 2014
• Aberrant EGFR signaling.
• Hyperplasia, hyperkeratosis, alopecia, rapid cutaneous
wound healing, and increased susceptibility to epithelial
cancers.
Rhbdf2P159/P159L C57BL/6J • Augmented secretion of AREG. Hosur et al., 2017a
• Aberrant EGFR signaling.
• Hyperplasia, hyperkeratosis, alopecia, and rapid cutaneous
wound healing.
Rhbdf2uncv/uncv BALB/c • The uncovered (Rhbdf2uncv/uncv ) spontaneous mouse
mutation, similarly to the Rhbdf2cub/cub mutation, results in
the loss of the cytosolic N-terminal domain of RHBDF2, and
consequently a loss-of-hair phenotype.
Li et al., 1999; Leilei et al.,
2014
Rhbdf2−/− C57BL/6 (?) • Forepaws and hind paws lack the normal epidermal
thickening and hyperpigmentation of the footpads.
Maruthappu et al., 2017
• Reduced keratin 16 expression in the footpads.
• Reduced stimulated secretion of EGFR ligands, including
AREG, heparin-binding EGF (HB-EGF), and transforming
growth factor alpha (TGFA).
Rhbdf2cub/cub AregMcub/Mcub C57BL/6J • A point mutation in the Areg gene, resulting in a premature
stop codon.
Johnson et al., 2003; Hosur
et al., 2014; Siggs et al., 2014
• Amphiregulin-null mice. No detectable Areg mRNA or
protein.
• Wavy hair coat owing to certain defects in EGFR signaling.
Rhbdf2P159/P159L AregMcub/Mcub C57BL/6J • A point mutation in the Areg gene, resulting in a premature
stop codon.
Hosur et al., 2017a
• Amphiregulin-null mice. No detectable Areg mRNA or
protein.
• Normal hair coat. No apparent defects in EGFR signaling.
Rhbdf2cub/cub ApcMin/+ C57BL/6J • Increases adenoma formation and reduces survival in
ApcMin/+ mice.
Hosur et al., 2014
MRL/MpJ-Rhbdf2cub/cub MRL/MpJ • Augmented secretion of AREG. Hosur et al., 2017b
• Aberrant EGFR signaling.
• Hyperplasia, hyperkeratosis, alopecia, and rapid cutaneous
wound healing.
Rhbdf2cub/cub Adam17flox/flox K14-Cre Mixed genetic background • Rhbdf2cub/cub mice lacking ADAM17 specifically in the skin. Hosur et al., 2018
• Loss of AREG secretion.
• Full hair coat, and loss of rapid wound-healing phenotype.
• Dermatitis and myeloproliferative disease in Rhbdf2cub/cub
mice lacking ADAM17 specifically in the skin.
and Rhbdf2P159L/P159L mice revealed a considerable increase in
the activity of downstream effectors of the epidermal EGFR
signaling pathway, including phospho-ERK1/2 and phospho-
mTOR, in Rhbdf2P159L/P159L mice. Together, these data suggest
that, analogous to the phenomena in human TOC mutations,
Rhbdf2P159L/P159L is a GOF mutation in the mouse Rhbdf2 gene,
and that these GOF mutations enhance secretion of AREG and
lead to constitutive activation of EGFR signaling to cause TOC.
Rhbdf2 Loss-of-Function Mice:
Rhbdf2−/−
Since GOF mutations in RHBDF2 cause skin hyperkeratosis
and hyperplasia (Blaydon et al., 2012; Saarinen et al., 2012;
Mokoena et al., 2018), Maruthappu et al. (2017) examined
whether loss of RHBDF2 has any effect on skin thickness. The
authors examined hematoxylin and eosin-stained skin sections
of adult Rhbdf2−/− and Rhbdf2+/+ mice and reported that
both the forepaws and hind paws, but not the back skin, of
Rhbdf2−/− mice present with an epidermis thinner than that
of Rhbdf2+/+ mice. Additionally, the authors showed that the
thinner epidermis in Rhbdf2−/− mice is associated with reduced
expression of cytoskeletal stress-associated protein keratin 16
(K16). Because of the reduced K16 expression associated with
loss of RHBDF2 and a thinner epidermis, the authors examined
K16 expression in the skin of human TOC patients using
immunohistochemistry and observed a considerable increase
in K16 expression. Collectively, these findings suggest that
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loss of RHBDF2 results in a thinner epidermis, and that,
correspondingly, GOF mutations in RHBDF2, such as those
observed in TOC, result in epidermal thickening through
interaction with and regulation of K16.
POTENTIAL MECHANISMS
Amphiregulin as a Functional Driver of
the Disease
Genetic modifier genes can accelerate disease progression, slow
down disease progression, or completely reverse a disease, and
thus provide valuable information regarding the underlying
biological pathways and the potential pharmaceutical targets.
The Rhbdf2cub mouse modifier gene Modifier of cub phenotype
(Mcub) was mapped to a position that coincides with a
cluster of four EGFR ligand-encoding genes on chromosome
5 (Johnson et al., 2003). A single Mcub allele in combination
with the Rhbdf2cub/cub genotype restores a full, wavy hair coat in
Rhbdf2cub/cub mice. Mcub was later identified as a point mutation
in the Areg gene that results in a premature stop codon, which
in turn results in the absence of any detectable Areg mRNA
or protein (Hosur et al., 2014). The rapid cutaneous wound-
healing and alopecia phenotype observed in Rhbdf2cub/cub mice
is lost when a single copy of the Mcub allele is present in
combination with the Rhbdf2cub/cub genotype. Concordantly,
in Rhbdf2P159L/P159L mice, genetic deletion of Areg restores
the normal skin phenotype (Hosur et al., 2017a), suggesting
that AREG mediates the hyperplasia, hyperkeratosis, alopecia,
and rapid wound-healing phenotypes in Rhbdf2P159L/P159L and
Rhbdf2cub/cub mice.
The Metalloprotease ADAM17 Is
Essential for Shedding of Amphiregulin
The metalloprotease ADAM17 is the major ectodomain sheddase
of AREG (Sunnarborg et al., 2002; Sahin et al., 2004; Sternlicht
et al., 2005). However, in studies using Rhbdf2cub/cub mice, we
(Hosur et al., 2014) and others (Leilei et al., 2014; Siggs et al.,
2014) found that ADAM17 activity is reduced in Rhbdf2cub/cub
mice, suggesting that RHBDF2 regulates secretion of AREG
independently of ADAM17 activity. Thus, to examine whether
RHBDF2 participates directly in shedding of EGFR ligands,
similarly to ADAM17, we generated Rhbdf2cub/cub mice with
ADAM17-deficient keratinocytes (Rhbdf2cub/cub Adam17flox/flox
K14-Cre) and studied their phenotype (Hosur et al., 2018). We
found that ADAM17 deficiency in the skin of Rhbdf2cub/cub
mice restored a full hair coat and impaired the rapid
wound-healing phenotype observed in Rhbdf2cub/cub mice,
demonstrating that ADAM17 is the major ectodomain sheddase
of AREG and that RHBDF2 does not directly participate
in the shedding of AREG. In addition, Rhbdf2cub/cub mouse
embryonic keratinocytes lacking ADAM17 failed to secrete
AREG both under stimulated and unstimulated conditions,
further demonstrating that ADAM17 is the principal sheddase
of AREG and, importantly, that RHBDF2 does not directly
participate in shedding of AREG (Figure 1C).
Tissue-Specific Role of the
RHBDF2-AREG-ADAM17-EGFR Pathway
The immune system plays a key role in the pathogenesis of
many proliferative skin diseases, including psoriasis and atopic
dermatitis (Reich, 2012; Czarnowicki et al., 2014). To determine
whether the hyperproliferative-skin and rapid-wound-healing
phenotypes mediated by RHBDF2-AREG in TOC are tissue-
specific and persist independently of the immune system, we
performed bone marrow and reciprocal skin graft experiments
(Hosur et al., 2017b). Bone marrow transfer from C57BL/6J(B6)-
Rhbdf2cub/cub donor mice to B6 recipient mice failed to transfer
the proliferative-skin and cutaneous regenerative phenotype in
B6 mice, suggesting that the surrounding microenvironment
or the immune system are unlikely to contribute to the TOC
phenotype. Moreover, reciprocal skin grafts—from B6 mice
to the dorsal skin of B6-Rhbdf2cub/cub mice and from B6-
Rhbdf2cub/cub mice to the dorsal skin of B6 mice—maintained the
phenotype of the donor mice. Together, these findings suggest a
tissue-specific function of the RHBDF2-AREG-ADAM17-EGFR
pathway in TOC.
Revisiting the Role of RHBDF2 in
Regulating AREG Secretion
The mechanism by which RHBDF2 regulates AREG secretion is
unclear. Substantial literature suggests that RHBDF2 regulates
ectodomain shedding of AREG secretion by controlling the
sheddase activity of ADAM17, the principle sheddase of AREG.
This model is based primarily on the hypothesis that RHBDF2
is essential for not only the maturation and trafficking but also
the activation of ADAM17 (Adrain et al., 2012; McIlwain et al.,
2012; Christova et al., 2013; Li et al., 2015; Cavadas et al., 2017;
Grieve et al., 2017). In further support of this model, it has been
shown that lack of RHBDF2 significantly decreases ADAM17-
dependent AREG secretion after stimulation with the protein
kinase C stimulant PMA, whereas GOF RHBDF2 mutations such
as those observed in human TOC enhance ADAM17 sheddase
activity to significantly increase AREG secretion (Brooke et al.,
2014). Consistent with this model, Maney et al. (2015) recently
showed in vitro that GOF mutations in RHBDF2 enhance
ADAM17 sheddase activity. Furthermore, it has been suggested
that RHBDF1, a paralog of RHBDF2, can compensate for the loss
of RHBDF2 in regulating ADAM17 maturation, trafficking, and
activity (Issuree et al., 2013).
Conversely, the following evidence argues against a role
for RHBDF1/RHBDF2 in regulating ADAM17 trafficking and
maturation or activity to drive AREG secretion. Strong in vivo
evidence includes the finding that mice overexpressing ADAM17
are viable and exhibit no overt phenotype (Yoda et al., 2013).
Concordantly, overexpression of ADAM17 in vivo does not
elicit any enhanced ADAM17 sheddase activity, or a significant
increase in secretion of AREG or other ADAM17 substrates
(Fukaya et al., 2013; Yoda et al., 2013). In support of these
observations, Dang et al. (2013) demonstrated in vitro that
phorbol-ester-stimulated shedding of EGF family members
and ADAM17 substrates AREG, HB-EGF, and TGFα occurs
independently of major changes in ADAM17 sheddase activity.
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Studies using Rhbdf1 knockout and/or Rhbdf1/Rhbdf2 double
knockout mice suggest that it is unlikely that RHBDF1 is
involved in regulating ADAM17 activity or compensating for its
loss. Neither Rhbdf1 knockout mice nor Rhbdf1/Rhbdf 2 double
knockout mice phenocopy Adam17 knockout mice; whereas
as Rhbdf1 knockout and Rhbdf1/Rhbdf2 double knockout mice
exhibit postnatal and embryonic lethality (Christova et al.,
2013), respectively, Adam17 knockout mice exhibit perinatal
lethality with an “open eyelids at birth” phenotype and hair-
follicle defects (Peschon et al., 1998). Together, these in vitro
and in vivo findings strongly argue against a role for RHBDF1
and RHBDF2 in either maturation or trafficking of ADAM17,
or regulation of its activity, to drive AREG secretion. We
propose that RHBDF2 likely regulates the availability of AREG
without directly influencing ADAM17 maturation or trafficking,
or sheddase activity (Figure 1C, right panel).
CONCLUSION
As mice and humans share between 95 and 98% of their
genes, mouse models of human skin diseases have been valuable
resources for studying the normal biological processes involved in
skin function, understanding the molecular mechanism causing
the diseases, identifying potential targets for intervention, and
testing therapeutics. While current murine models of human
TOC, both spontaneous mutant and genetically engineered
mice, do not recapitulate all characteristics of the human
disease, these models have yielded valuable insights into
disease mechanisms, including the identification of AREG as
a functional driver of the disease, verification of the essential
role of metalloprotease ADAM17 in shedding of AREG,
demonstration of the susceptibility of mice carrying Rhbdf2
GOF mutations to epithelial cancer, and determination of
the tissue-specific role of the RHBDF2-AREG-ADAM17-EGFR
pathway. In addition, by further leveraging these murine models
in future studies, researchers can continue to generate and
test mechanistic hypotheses, and study the physiological and
pathogenic molecular machinery underlying the role of the
RHBDF2-regulated EGFR signaling pathway in TOC, and in
other skin diseases and epithelial cancers.
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